Martínez C - Search Results

1

Influence of cytochrome P450 CYP2C9 genotypes in lung cancer risk.

García-Martín E, Martínez C, Ladero JM, Gamito FJ, Rodriguez-Lescure A, Agúndez JA. García-Martín E, et al. Among authors: martinez c. Cancer Lett. 2002 Jun 6;180(1):41-6. doi: 10.1016/s0304-3835(02)00015-0. Cancer Lett. 2002. PMID: 11911968

2

Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use.

Martínez C, Blanco G, Ladero JM, García-Martín E, Taxonera C, Gamito FG, Diaz-Rubio M, Agúndez JA. Martínez C, et al. Br J Pharmacol. 2004 Jan;141(2):205-8. doi: 10.1038/sj.bjp.0705623. Epub 2004 Jan 5. Br J Pharmacol. 2004. PMID: 14707031 Free PMC article.

3

Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.

García-Martín E, Martínez C, Tabarés B, Frías J, Agúndez JA. García-Martín E, et al. Among authors: martinez c. Clin Pharmacol Ther. 2004 Aug;76(2):119-27. doi: 10.1016/j.clpt.2004.04.006. Clin Pharmacol Ther. 2004. PMID: 15289789

4

The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects.

Martínez C, García-Martín E, Blanco G, Gamito FJ, Ladero JM, Agúndez JA. Martínez C, et al. Br J Clin Pharmacol. 2005 Jan;59(1):62-9. doi: 10.1111/j.1365-2125.2004.02183.x. Br J Clin Pharmacol. 2005. PMID: 15606441 Free PMC article.

5

Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals.

García-Martín E, Martínez C, Ladero JM, Agúndez JA. García-Martín E, et al. Among authors: martinez c. Mol Diagn Ther. 2006;10(1):29-40. doi: 10.1007/BF03256440. Mol Diagn Ther. 2006. PMID: 16646575 Review.

6

Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8.

García-Martín E, Pizarro RM, Martínez C, Gutierrez-Martín Y, Pérez G, Jover R, Agúndez JA. García-Martín E, et al. Among authors: martinez c. Pharmacogenomics. 2006 Jun;7(4):575-85. doi: 10.2217/14622416.7.4.575. Pharmacogenomics. 2006. PMID: 16753005

7

Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.

Gervasini G, García-Martín E, Ladero JM, Pizarro R, Sastre J, Martínez C, García M, Diaz-Rubio M, Agúndez JA. Gervasini G, et al. Among authors: martinez c. BMC Cancer. 2007 Jul 2;7:118. doi: 10.1186/1471-2407-7-118. BMC Cancer. 2007. PMID: 17605821 Free PMC article.

8

Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding.

Blanco G, Martínez C, Ladero JM, Garcia-Martin E, Taxonera C, Gamito FG, Diaz-Rubio M, Agundez JA. Blanco G, et al. Among authors: martinez c. Pharmacogenet Genomics. 2008 Jan;18(1):37-43. doi: 10.1097/FPC.0b013e3282f305a9. Pharmacogenet Genomics. 2008. PMID: 18216720

9

Effect of neurotransmitters on NADPH-cytochrome P450 reductase in vitro activity.

Gervasini G, Martinez C, Benitez J, Agúndez JA. Gervasini G, et al. Among authors: martinez c. Drug Metab Lett. 2007 Aug;1(3):172-5. doi: 10.2174/187231207781369762. Drug Metab Lett. 2007. PMID: 19356039

10

Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?

Agúndez JA, García-Martín E, Martínez C. Agúndez JA, et al. Among authors: martinez c. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):607-20. doi: 10.1517/17425250902970998. Expert Opin Drug Metab Toxicol. 2009. PMID: 19422321 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,282 results

Search Page

Filters